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In Brief Shankar et al. show that RAS interacts with AGO2, a key component of the RNAsilencing machinery. Interaction of oncogenic KRAS with AGO2 in the endoplasmic reticulum inhibits AGO2 function, elevates mutant KRAS protein levels, and enhances cellular transformation. AGO2 is required for maximal KRAS-mediated oncogenesis.
INTRODUCTION
Approximately one-third of human cancers harbor an oncogenic mutation in HRAS, KRAS, or NRAS (Balmain and Pragnell, 1983; Karnoub and Weinberg, 2008; Pylayeva-Gupta et al., 2011) . The tumor types most frequently harboring RAS mutations, predominantly in KRAS, include pancreatic, lung, and colon carcinoma, among others (COSMIC, 2013; Hand et al., 1984; Karachaliou et al., 2013; Lauchle et al., 2006; Lö hr et al., 2005) . RAS genes encode a family of small GTPases (Sweet et al., 1984) that transduce extracellular growth signals by cycling between an active GTP-bound state and an inactive GDP-bound state (Karnoub and Weinberg, 2008; Schubbert et al., 2007) . Oncogenic Ras proteins exhibit reduced intrinsic GTPase activity and are resistant to negative regulation by GTPase-activating proteins (GAPs) such as p120GAP and neurofibromin (Cichowski and Jacks, 2001 ). Constitutively elevated levels of Ras-GTP aberrantly activate downstream effector pathways that promote neoplastic transformation (Karnoub and Weinberg, 2008; Shaw and Cantley, 2006; Trahey and McCormick, 1987) . Despite extensive characterization of the Ras/GAP molecular switch(es) and downstream signaling axes, therapeutic targeting of RAS-driven cancers remains elusive (Baines et al., 2011; Downward, 2003; Stephen et al., 2014) .
The oncogenic activity of RAS-GTP is mediated through canonical effectors including RAF, PI3 kinase (PI3K), and Ral-GDS (Cox and Der, 2010; Karnoub and Weinberg, 2008) , and other effectors have been described in various contexts (Gysin et al., 2011) . RAS effectors bind through the conserved Switch I and Switch II domains and drive cellular transformation by activating downstream kinases and GTPase-signaling modules, the best known of which are the RAF/MEK/ERK (mitogen activation protein [MAP] kinase) and the PI3K/Akt signaling cascades. RAS interactors have been identified using conventional approaches of ectopically expressed epitope-tagged RAS constructs (Goldfinger et al., 2007; Vasilescu et al., 2004) . Here, we employed coimmunoprecipitation followed by mass spectrometry (coIP MS) to analyze the endogenous interactome of RAS in a panel of lung and pancreatic cancer cell lines representing the spectrum of both KRAS mutation and dependency status. Surprisingly, the most prominent interacting protein, across all cell lines analyzed, was EIF2C2, commonly known as Argonaute 2 (AGO2), a key effector of the RNA-silencing pathway. Interestingly, a role for AGO2 in RAS-induced senescence has been described recently (Benhamed et al., 2012; Yang et al., 2014) . Also, phosphorylation of AGO2 by MAPK/PI3K pathway activators has been shown to alter its microRNA-related function through different mechanisms (Horman et al., 2013; R€ udel et al., 2011; Shen et al., 2013; Zeng et al., 2008) , portending a broader, direct interface between intracellular signaling and RNA-silencing mechanisms (Paroo et al., 2009) . Considering the potential functional implications of RAS-AGO2 interaction, here we corroborated and characterized this interaction in detail.
RESULTS

Endogenous RAS and AGO2 Interaction
To analyze RAS-interacting proteins in an endogenous setting, we first used the pan-RAS antibody RAS10 (Cheng et al., 2011) , which efficiently immunoprecipitates RAS proteins by binding to the Switch I domain (amino acids [aa] 32-40; Figures S1A-S1C). Co-immunoprecipitation of RAS followed by tandem mass spectrometry (RAS coIP MS) was performed as outlined in Figure S1D using a panel of ten lung and pancreatic cancer cell lines of known KRAS mutation status (Table  S1) cell lines, as expected (Table S2) . To minimize individual cell-specific observations in the endogenous system employed, we focused on observations common across different cell lines. Intriguingly, peptides spanning EIF2C2 protein, commonly known as AGO2, the catalytic component of the RNA-induced silencing complex (RISC), were observed in the RAS coIP MS of all cancer cell lines (n = 10) tested, as well as in NIH 3T3 cells expressing KRAS WT or KRAS G12V (Figure 1A) . Remarkably, only the RAS and AGO2 peptides were detected in every cell line tested, with cumulative spectral counts of 576 and 229, respectively. Other interactors detected in five or more of the 12 cell lines are tabulated in Table  S2 . The significant lack of peptides spanning the RAS effectors like RAF/PI3K in the endogenous mass spectrometric analysis is due to the RAS10 antibody binding the Switch I domain, preventing effector binding ( Figure S1C ). The lack of other RAS regulators like SOS1 and NF1 that associate with RAS through the Switch II domain may be due to their transient association and plasma-membrane-localized/cell-specific expression. Interestingly, we did not detect peptides spanning AGO2 in our earlier mass-spectrometric-based studies involving ERG, PRC complex protein EED (Brenner et al., 2011; Cao et al., 2014) , and at least four other protein pull-down data sets (data not shown), indicating the specificity of AGO2 coIP with RAS. Analyzing the RAS coIP MS data further, we noted peptides mapping uniquely to all three RAS family members, namely KRAS, NRAS, and HRAS, were readily detected across the cell line panel ( Figure 1B ). In contrast, almost all uniquely mapping peptides to AGO family proteins were specific to AGO2 in all of the 12 cell lines (except for a single unique peptide that mapped to AGO1 in one sample; Figure 1B ).
The putative endogenous interaction between RAS and AGO2 was corroborated by reciprocal IPs using two different antibodies for each, in two different lung cancer cell lines, H358 and H460, harboring distinct KRAS mutations ( Figure 1C) . Further, consistent with the coIP MS analyses ( Figure 1A) , the RAS-AGO2 interaction was readily detected by coIP followed by immunoblot analysis in two cell lines with wild-type KRAS and representative lung and pancreatic cancer cells harboring various activating mutations of KRAS ( Figure 1D ). The observed RAS-AGO2 interaction was maintained even under highly stringent conditions of 1 M NaCl ( Figure S1E ). The RAS-AGO2 coIP was maintained in the presence of RNase, suggesting that the interaction is independent of AGO2 interaction with RNA ( Figures  S1F and S1G ). To demonstrate further specificity of this interaction, we overexpressed FLAG-tagged AGO2 construct in HEK293 cells and detected RAS in FLAG immunoprecipitates ( Figure S1H ). We also performed the coIP analysis in genetically engineered ''RASless'' mouse embryonic fibroblast cells (Drosten et al., 2010) and failed to detect this interaction upon ablation of KRAS expression ( Figure S1I ), further establishing the specificity of the RAS-AGO2 interaction.
Co-localization of RAS and AGO2 in the Membrane Component of Endoplasmic Reticulum RAS proteins are known to localize to the plasma membrane and membranes of various intracellular organelles like the endoplasmic reticulum (ER), Golgi, and mitochondria with distinct signaling outputs (Bivona et al., 2006; Prior and Hancock, 2012) . AGO2 is known to assemble in the ER (Kim et al., 2014; Stalder et al., 2013) , cytoplasm (Hö ck et al., 2007) , and nucleus (Dudley and Goldstein, 2003; Gagnon et al., 2014) . Consistent with this observation, fractionation of H358 cells revealed that RAS was restricted mainly to the membrane (plasma membrane and endomembrane) fraction along with AGO2, which was also detected in the cytoplasmic and nuclear extracts (Figure 2A ). Sedimentation analyses using sucrose density gradient showed that total RAS and mutant KRAS predominantly co-sedimented with AGO2 in smaller-molecular-weight fractions (Complex I; Figure 2B ) as defined by a previous study (Hö ck et al., 2007) .
Next, to assess co-localization of endogenous RAS and AGO2, we performed indirect immunofluorescence using RAS10 and AGO211A9 (R€ udel et al., 2008) Figure S2 . different cells. To ascertain the specificity of RAS10 Ab, antigenic peptides were used for competition prior to immunofluorescence analysis ( Figure S2A ); in addition, AGO211A9 has been demonstrated to be a highly specific, validated monoclonal antibody for immunofluorescence detection of AGO2 (R€ udel et al., 2008) . In H358, MIA PaCa-2, and DLD-1 cells ( Figure 2C ), RAS staining was visible both at the plasma membrane and intracellular regions, whereas only cytoplasmic staining was detected for AGO2. Manders co- efficient analysis indicative of signal overlap between the two proteins was determined to be 0.53, 0.65, and 0.60 in H358, MIA PaCa-2, and DLD-1 cells, respectively (where 1 is considered complete overlap and 0 is considered no overlap). These findings suggest significant co-localization of RAS and AGO2 predominantly in the intracellular perinuclear regions of cells ( Figure 2C ).
Given that cytoplasmic RAS is restricted to the endomembrane bound organelles, we performed a three-color immunofluorescence staining for RAS and AGO2 along with specific protein markers of different organelles in MIA PaCa-2 cells. Whereas we observed a significant signal overlap between RAS, AGO2, and ER marker (PDI; Figures 2D and S2B), Manders coefficient values were minimal for Golgi (RCAS1), endosomal (Rab5/7/11), or mitochondrial (COX4) markers (Figures S2B and S2C) . This suggests that endogenous RAS and AGO2 are predominantly found in the ER (Manders coefficient for both RAS in ER and AGO2 in ER was 0.62 each), where they co-localize. Hence, along with the cell fractionation analyses, these immunofluorescence data suggest that a subset of RAS proteins co-localizes with AGO2 in the endomembranous components of the ER.
AGO2 Binds RAS through Its N-Terminal Wedge Domain
To identify specific region(s) in AGO2 involved in the interaction with RAS, we employed a panel of FLAG-epitope-tagged AGO2 expression constructs (summarized in the schematic in Figure 3A ). RAS coIP analysis of the FLAG-tagged AGO2 deletion constructs showed that the N-terminal domain of AGO2 was necessary ( Figure 3B ) and sufficient ( Figure S3A ) for RAS binding. Further analysis of a panel of deletion constructs spanning the N-terminal domain suggested that the region spanning 50-139 aa was critical for RAS binding ( Figure S3B ). Interestingly, this aa stretch was recently shown to be part of the ''wedging'' domain, important for microRNA duplex unwinding prior to RISC assembly (Kwak and Tomari, 2012) . To further define AGO2 residues critical for interaction with RAS, we focused on the 50-139 aa stretch that is uniquely present in AGO2 (and not in AGO1, 3, or 4) based on the fact that, among the Argonaute family proteins, AGO2 was almost singularly represented in the RAS coIP MS data. ClustalW alignment of all human Argonaute proteins (AGO1-4) identified ten residues unique to AGO2 in this region ( Figure S3C ). Alanine substitution of each of the ten residues was followed by RAS coIP analysis, and aa K112 and E114 of AGO2 were found to be critical for a direct association with RAS ( Figure 3C ).
Y64
Residue within the Switch II Domain of KRAS Is Critical for Direct AGO2 Binding In a parallel analysis aiming to define the residues in RAS critical for AGO2 association, we first employed two RAS antibodies that bind exclusively either to the Switch I (RAS10 mAb) or the Switch II (Y13-259) domains (summarized in Figure 4A ). Whereas both antibodies efficiently immunoprecipitated RAS in H358 cell lysates, AGO2 was present only in IPs with Switch-I-specific RAS10 Ab and not in Switch-II-specific Y13-259 Ab ( Figure 4B ), suggesting that the Switch II domain in RAS is critical for AGO2 interaction. Next, we hypothesized that, if the RAS-AGO2 interaction is restricted through contacts with the Switch II domain, we may be able to detect AGO2 in RAS-GTP complexed with RAF, on RAS-binding domain (RBD) agarose beads. As predicted, we were able to detect AGO2 on RAS-GTP bound to RBD-agarose in H358 (KRAS
G12C
) cells ( Figure S4A ), further supporting that AGO2 binds to the Switch II domain of GTP-bound KRAS. Next, we sought to determine the specific residues in the Switch II region of KRAS involved in its interaction with AGO2, using in vitro coIP assays. Purified recombinant KRASG12V or KRASWT proteins were incubated with varying concentrations of AGO2 protein followed by RAS immunoprecipitation. We observed a concentration-dependent, direct interaction between recombinant AGO2 and both the wild-type and mutant KRAS proteins ( Figure 4C ). Further, in vitro coIP of recombinant AGO2 protein with the panel of Switch II mutant KRAS proteins showed that altering the Y64 residue (but not the neighboring aa) significantly reduced KRAS binding to AGO2 ( Figure 4D ). To further substantiate this observation, and to obviate potential technical concerns inherent in antibody-based coIP, we carried out an antibody-independent pull-down assay using recombinant His-tagged AGO2 protein bound to Ni-NTA beads. Consistent with the in vitro coIP analyses, the His-tagged AGO2 pull-down assay also showed specific dependency of AGO2-RAS binding on the Y64 residue ( Figure 4E ).
To assess whether GDP/GTP loading of KRAS may influence the AGO2 interaction in vitro, we carried out in vitro coIP analyses using KRASWT and KRASG12V proteins loaded with GDP/GTPgS and as seen in Figure S4B . Our results showed that AGO2 binding was agnostic to nucleotide loading status of KRAS. Similarly, both the KRASWT and KRASG12V proteins were observed to bind to His-tagged AGO2, independent of the nucleotide loading on KRAS ( Figure S4C ). To validate the efficiency and specificity of nucleotide loading onto KRAS proteins, we performed RAF-RBD pull-down assays and observed the expected differential between GDP-and GTP-bound KRAS with respect to RAF-RBD binding ( Figure S4D ). Thus, these data define the aa in RAS (Y64) and AGO2 (K112/E114) as critical for the RAS-AGO2 interaction.
Reduced RISC Activity Elevates Oncogenic KRAS Levels, Making AGO2 Essential for Mutant KRASDependent Cell Proliferation Next, we set out to analyze functional implications of the RAS-AGO2 interaction, particularly in the context of KRAS-driven transformation. To this end, we first carried out knockdown of AGO2 in H358 lung cancer cells that harbor a homozygous KRAS mutation and are known to be KRAS dependent (Symonds et al., 2011) . Whereas the microRNA let-7/AGO2 axis is reported to negatively regulate wild-type RAS levels (Diederichs and Haber, 2007; Johnson et al., 2005) , we observed a remarkable reduction in mutant KRAS protein levels in H358 cells with AGO2 knockdown ( Figure 5A , left panel). Conversely, overexpression of AGO2 in the same cells led to elevated levels of KRAS, implying a positive regulation of mutant KRAS levels by AGO2 ( Figure 5A , right panel). Consistent with these observations, knockdowns of AGO2 and/or KRAS in H358 cells (using two independent shRNAs; Figures S5A and S5B) showed reduced rates of cell proliferation whereas AGO2 overexpression resulted in increased cell proliferation ( Figure 5B ). Furthermore, AGO2 knockdown reduced the ability of H358 cells to form colonies in colony formation assays ( Figure 5C ) and resulted in a marked reduction in levels of known mediators of KRAS signaling, including p-Akt, p-mTOR, and p-RPS6 based on our analysis with Pathscan intracellular signaling array (Cell Signaling Technology; Figures 5D, S5C, and S5D). Interestingly, similar AGO2 depletion experiments (using the same shRNAs described above) in KRAS-independent H460 lung cancer cells, which also harbors a mutant KRAS, did not affect cell proliferation, colony formation ( Figure 5E ), or intracellular signaling (Figures 5F and S5E) . Phenotypic effects upon AGO2 knockdown in the context of KRAS dependency were also observed in pancreatic cancer cell lines, where knockdown of either KRAS or AGO2 dramatically reduced cell proliferation in mutant KRAS-dependent MIA PaCa-2 cells, but not in mutant KRAS-independent PANC-1 cells ( Figures 5G, S5A , and S5B). Further, AGO2-depleted MIA PaCa-2 cells failed to establish xenografts in SCID mice ( Figure 5H ), with a concomitant reduction in KRAS protein levels ( Figure 5H , inset). These data suggest that KRAS-dependent cancer cells manifest a coincident dependence on AGO2 to maintain oncogenic KRAS protein levels and support a functional role for AGO2 in potentiating the oncogenic activities of mutant KRAS.
To directly address the consequence of mutant KRAS binding at the N-terminal of AGO2, critical for microRNA duplex unwinding (Kwak and Tomari, 2012; Wang et al., 2009) guide-to-passenger strand ratio was estimated 30 min after injection, where a 1:1 ratio was considered as no unwinding whereas higher ratios indicate active unwinding. As seen in Figure 5I (left) , the formation of single-stranded (ss) RNA molecules from double-stranded (ds) let-7 substrates, a key step in the formation of active RISC, was attenuated in DLD-1 MUT/WT cells (ratio = 1.3). Duplex unwinding was restored in isogenic cells lacking mutant KRAS (À/WT; ratio = 5.7). Biochemical assays using cellular lysates followed by gel electrophoresis also showed reduced let-7 unwinding in DLD-1 MUT/WT cells ( Figure 5I , right), even though the RAS-AGO2 interaction was detected in both DLD-1 isogenic cells ( Figure S5F ). Additionally, the let-7 unwinding assay was performed in mouse embryonic fibroblasts lacking AGO2 (MEFAGO2À/À) and MEFAGO2À/À reconstituted with AGO2 (MEFAGO2À/À + AGO2; Broderick et al., 2011) to demonstrate that the microRNA unwinding assay is AGO2 dependent (Figures S5G and S5H Figure 6A ). In contrast, AGO2 overexpression did not enhance BRAF
V600E
-driven focus formation ( Figure S6A ), suggesting that AGO2 specifically potentiates RAS-mediated oncogenesis, most likely as a result of its direct interaction with RAS. In vivo experiments using a mouse xenograft model also showed a significant increase in tumor growth with cells expressing KRAS G12V +AGO2 compared to KRAS G12V +vector control (Figure S6B ). As expected, in these experiments, cells expressing either KRAS WT or AGO2 alone did not develop tumors. Consistent with AGO2 overexpression in H358 cells ( Figure 5A ), immunoblot analysis of NIH 3T3 cells overexpressing AGO2 showed an increase in KRAS protein levels ( Figure 6B ). Figure S6F ), suggesting an inhibition of AGO2 function in oncogenic KRAS-expressing cells.
To further investigate a requirement for an AGO2 interaction in KRAS G12V -driven transformation, we first performed in vitro RAS coIP assays using mutant KRASG12D and the double mutant KRASG12DY64G, which has previously been shown to have limited oncogenic potential (Shieh et al., 2013) . Whereas KRASG12D binds AGO2, KRASG12DY64G failed to bind AGO2 ( Figure S6G ). Transfecting a retroviral vector encoding KRAS G12VY64G double mutant into NIH 3T3 cells failed to generate foci ( Figure 6D ). As an important corollary to our hypothesis that mutant KRAS-AGO2 interaction leads to elevated mutant KRAS protein levels, the KRAS G12VY64G stably expressing cells also showed much-lower levels of KRAS protein than KRAS G12V -expressing cells ( Figure 6E , top panel show the characteristic morphology of KRAS G12V cells (Figure 6E, bottom panel) . In vivo, these cells also failed to establish tumors in the xenograft mouse model ( Figure 6F ), supporting a critical role for Switch II region (Y64) in KRAS-driven transformation, including its association with AGO2.
Whereas NIH 3T3 cells stably expressing KRAS G12V showed reduced let-7 levels, KRAS
G12VY64G
-expressing cells, which do not allow for the mutant KRAS-AGO2 interaction, showed no change in let-7 expression, providing evidence for a direct role of mutant KRAS in the modulation of microRNA levels in this model ( Figure S6K ). Cognate analysis of the levels of let-7 target transcripts (Lee and Dutta, 2007) showed an almost log-fold change in the mRNA levels of HMGA1 and HMGA2 only in KRAS G12V -expressing cells ( Figure S6L ). Together, our data using the KRAS G12VY64G mutant and let-7 levels as readout of AGO2 function broadly support the conclusion that mutant KRAS, through its direct association, inhibits AGO2 activity.
To more directly explore the potential effect of KRAS G12V on functional messenger ribonucleoprotein particles (mRNPs), we exploited a recently described method for intracellular singlemolecule, high-resolution localization and counting (iSHiRLoC) . Quantitation of foci from two independent experiments (right) is shown. Indicated p value was calculated using two-sided Student's t test. (E) KRAS immunoprecipitation (using sc-521 pAb) followed by immunoblot analysis (RAS10 Ab) showing low levels of oncogenic KRAS protein expression in NIH 3T3 cells stably expressing KRAS
. RAS-GTP levels were assessed using RBD agarose beads. Signaling through phospho-Akt and phospho-ERK activation was performed after serum starvation by immunoblot analysis. Lower panel shows morphology of indicated stable lines grown in 10% serum upon crystal violet staining. (F) In vivo growth of NIH 3T3 cells stably overexpressing KRAS G12V and KRAS G12VY64G in nude mice. For each group (n = 8), 500,000 cells were injected and average tumor volume (in mm 3 ) was plotted on y axis and days after injection on the x axis.
(G) (Left) Representative 3.14 3 3.14 mm 2 regions from NIH 3T3 (top left), NIH 3T3-KRAS WT (top right), NIH 3T3-KRAS G12V (bottom left), and NIH 3T3-KRAS G12V,Y64G cells (bottom right) that were imaged 4 hr (h) after microinjection of let-7-a1-Cy5. Individual particle tracks (colored) and their net displacements of microRNAs (Pitchiaya et al., 2012 (Pitchiaya et al., , 2013 . Diffusion coefficients of microinjected fluorophore-labeled let-7a molecules suggest that, in NIH 3T3 cells expressing KRAS WT , let-7a assembles into both ''fast'' (low molecular weight) and ''slow'' (high molecular weight) mRNA-protein complexes (mRNPs; Figures 6G and  S6M ). By contrast, in cells expressing KRAS
G12V
, let-7a manifested predominantly in fast-moving complexes, suggesting that let-7a is unable to accumulate in larger mRNPs (known to be functional RISC; Pitchiaya et al., 2012 Pitchiaya et al., , 2013 in an oncogenic KRAS setting. Importantly, in cells expressing KRAS
G12VY64G
, let-7a accumulates in both fast and slow mRNPs, further implicating that a direct interaction between mutant KRAS and AGO2 is essential to prevent functional RISC assembly. Thus, the NIH 3T3 overexpression model suggests that, through its interaction with AGO2, mutant KRAS modulates levels of mature microRNAs likely due to its ability to inhibit an early step of RISC assembly.
AGO2 Interaction Is Required to Maximize Oncogenic Potential of Mutant KRAS
To further underscore the role of AGO2 in KRAS
G12V
-driven oncogenesis, we generated NIH 3T3 cells with AGO2 knockout (NIH 3T3 AGO2À/À) using the CRISPR/Cas9 methodology (Ran et al., 2013 ; Figure S7A ). Validation of AGO2 knockout in NIH 3T3 AGO2À/À cells was performed at the DNA, RNA, and protein levels ( Figures S7B-S7D ). Sucrose density sedimentation analysis of NIH 3T3 AGO2À/À showed that, in contrast to NIH 3T3 parental cells, RAS is restricted largely to the first four fractions of the gradient with minimal overlap with AGO1 complexes, indicating that RAS associates with higher-molecular-weight fractions through its interaction with AGO2 ( Figure 7A ). NIH 3T3 AGO2À/À cells had lower levels of let-7 family microRNAs ( Figure S7E) , consistent with previous studies demonstrating that a loss of AGO2 results in reduction of absolute levels of all microRNAs (Diederichs and Haber, 2007) . In NIH 3T3 AGO2À/À cells, the reduction of let-7 family microRNA levels also resulted in a concomitant increase in let-7 target (HMGA1/HMGA2) transcript levels ( Figure S7F ).
Despite reduced levels of microRNAs, KRAS G12V expression in the NIH 3T3 AGO2À/À cells showed a markedly reduced ability to generate foci compared to parental NIH 3T3 ( Figures  7B and S7G ). Partial rescue of the ability to establish foci in these cells was achieved by overexpression of AGO2 or AGO2 K98A (which permits RAS interaction), but not the AGO2 K112A mutant (which does not bind RAS; Figure 3C ). These observations also support the notion that a direct association of oncogenic KRAS and AGO2 is required for mutant KRAS-driven transformation. In addition, NIH 3T3 AGO2À/À cells stably expressing KRAS
did not display the characteristic morphology of NIH 3T3 KRAS G12V cells ( Figure 7C, Figure 7D ). Reduced activation of phospho-Akt signaling by mutant KRAS and a slight increase in phospho-ERK signaling in NIH 3T3 AGO2À/À cells suggests that AGO2 plays an essential role in modulating the signaling output of mutant KRAS. Taken together, we have established AGO2 as a critical regulator of RAS-GTP in cells, and our study posits an essential role for the KRAS-AGO2 interaction in oncogenic KRAS-driven cellular transformation.
DISCUSSION
RAS, one of the first proto-oncogenes identified (DeFeo et al., 1981) , has emerged as one of the genes with most-frequent recurrent mutations in a broad spectrum of human cancers. In recent years, there is a renewed interest in targeting RAS to alter its status from an undruggable to druggable candidate (Burns et al., 2014; Ostrem et al., 2013; Spiegel et al., 2014; Stephen et al., 2014; Sun et al., 2012) . In this context, discovery of novel endogenous interactors of RAS could potentially advance our understanding of RAS biology and provide additional therapeutic avenues.
Here, we identify the interaction of RAS with AGO2, a key mediator of RNA-based gene silencing (Czech and Hannon, 2011; Peters and Meister, 2007; Wilson and Doudna, 2013) . Like guanine nucleotide exchange factors (GEFs), AGO2 binds RAS-GTP and RAS-GDP and likely interacts functionally with both wild-type and oncogenic RAS proteins (Jeng et al., 2012; Margarit et al., 2003) . Furthermore, AGO2 and RAS co-localize in the ER, known sites for both RAS trafficking and AGO2 RISC activity. The KRAS-AGO2 interaction involves Y64 in the Switch II domain of KRAS and K112-E114 residues in the N-terminal Wedge domain of AGO2 ( Figure 7E) . Functionally, the mutant KRAS-AGO2 interaction is critical for KRAS-mediated oncogenesis. Mechanistically, mutant KRAS binding attenuates AGO2 N-terminal-dependent microRNA duplex unwinding, critical for functional RISC assembly. Reciprocally, AGO2 modulates mutant-KRAS-mediated signaling output, particularly the AKT-mTOR pathway.
Our study focused on analyzing endogenous interactors of RAS, common across a panel of cancer cells spanning the spectrum of KRAS aberrations. To the best of our knowledge, this is the first study using endogenous RAS as bait for mass spectrometric analyses, as all previous coIP MS analyses used N-terminal epitope-tagged HRAS, MRAS, or RRAS ectopically expressed in NIH 3T3 cells (Goldfinger et al., 2007; Vasilescu et al., 2004) . Studies using tagged AGO2 as bait for mass spectrometry have also been reported (MacRae et al., 2008; Meister et al., 2005) and, as a 25-kDa cutoff was employed for analyses, may have missed the detection of the 21 kDa RAS protein. In this study, the pull-down of AGO2 using multiple independent antibodies consistently co-precipitated RAS ( Figure 1C ), and we found that this interaction is direct, as assessed using purified components (Figure 4) . Endogenously, the RAS-AGO2 interaction is readily detected in both cancer and benign cells, independent of KRAS mutation status ( Figure 1D ), portending a fundamental role for this interaction in the cell.
KRAS interacts with AGO2 through the Switch II domain, the Y64 residue being critical for its AGO2 association. The Switch II domain and particularly Y64 was recently demonstrated to be critical in hematopoietic malignancies, where KRAS G12DY64G mutant expressed at lower levels compared to KRAS G12D (Shieh et al., 2013) , much like we observed in our NIH 3T3 model, extending a role for the KRAS-AGO2 interaction in models other than lung and pancreas. It should be noted that the Switch II domain in RAS is the site for allosteric regulation through its binding to various regulators and may contribute to the biological effects observed in these studies. Yet, this study provides a first instance where the mutant KRAS Switch II domain (and Y64) has a direct bearing on RISC assembly through its association with AGO2.
The AGO2 N-terminal domain represents the most-distinct region in the highly conserved AGO protein family. A recent report (Kwak and Tomari, 2012) suggests that the region we identified in AGO2 as critical for RAS binding (i.e., the ''wedge domain'') is important for small RNA duplex unwinding, a prerequisite for RISC assembly. Using isogenic lines, we demonstrate that mutant KRAS, but not wild-type KRAS, interaction with AGO2 attenuates microRNA duplex unwinding function with a direct bearing on AGO2-RISC assembly. Inhibition of RISC assembly by mutant KRAS may be the critical step that likely contributes to global loss of microRNA levels and downstream effects on increased protein translation of target mRNAs, features of human tumors (Lu et al., 2005) . Because we have used mutant KRAS constructs that do not have 3 0 UTR regions that can bind microRNAs, it remains unclear how AGO2 elevates mutant KRAS levels ( Figures 5A and 6B ) to increase its transformation potential.
Recent studies have shown that KRAS, but not HRAS, translation is tightly regulated by rare synonymous codons of the KRAS transcript (Lampson et al., 2013; Pershing et al., 2015) , suggesting a significant role for KRAS regulation at a level prior to its better-characterized post-translational modifications. An association of mutant KRAS with the RNA machinery through binding to HNRNPA2B1 was also reported (Barceló et al., 2014) , supporting a likely interface of RAS with the RNA-processing machinery, including the hub protein AGO2 as observed in our study. The EGFR kinase was also recently shown to phosphorylate AGO2 in response to hypoxia, leading to inhibition of AGO2-mediated microRNA processing (McCarthy, 2013; Shen et al., 2013) . Similarly, Akt was shown to phosphorylate AGO2 to inhibit AGO2-mediated mRNA endonucleolytic activity (Horman et al., 2013) . Interestingly, AGO2 phosphorylation also leads to inhibition of microRNA loading into RISC complexes in the presence of mutant HRAS G12V . The identification of AGO2 as a critical partner of RAS further provides a direct mechanistic link between RAS oncogenic signaling and RNA silencing. Further illumination of such integral effector mechanisms of RAS may inform novel approaches to therapeutically target this frequently mutated cancer pathway.
EXPERIMENTAL PROCEDURES
Co-immunoprecipitation and Tandem Mass Spectrometric Analysis
Methods used for immunoprecipitation with RAS/control IgG followed by tandem mass spectrometric analysis and database searching are schematically outlined in Figure S1D . Complete data of the peptides represented in the RAS coIP mass spectrometric analysis from the different cell lines are provided in Table S5 .
Immunoprecipitation and Western Blot Analysis
Routine methods to immunoprecipitate proteins were employed and detailed in the Supplemental Experimental Procedures. Antibodies used in the study are detailed in Table S3 .
RAS-GTP Pull-Down Assay
The RAS-RAF interaction was studied using the RBD agarose beads as per manufacturer's instructions (Millipore) and detailed in the Supplemental Experimental Procedures.
Focus Formation Assay
Foci formation assays were performed by transfecting/co-transfecting (the indicated constructs) 150,000 early passage NIH 3T3 cells in 6-well dishes using Fugene HD (Promega). After 2 days, cells were trypsinized and plated onto 150 mm dishes containing 4%-5% calf serum. The cells were maintained under low serum conditions, and medium was refreshed every 2 days. After 21 days in culture, the plates were stained for foci using crystal violet.
Generation of NIH 3T3 AGO2À/À Line AGO2-knockout NIH 3T3 cells were generated by CRISPR-Cas9-mediated genome engineering (Ran et al., 2013) . Genomic regions in murine AGO2 between exons 8 and 9 and between exons 11and 12 were targeted for deletion using primers TCCTTGGTTACCCGATCCTGG and AGAGACTATCTG CAACTATGG, respectively (PAM motif underlined). Selection of clones is detailed in the Supplemental Experimental Procedures.
iSHiRLoC Analyses Oligos (let-7-a1 guide: P-UGA GGU AGU AGG UUG UAU AGU U-X Cy5, where X = Cy3 or Cy5; let-7-a1-passenger: P-CUA UAC AAU CUA CUG UCU UUC C-Y, where Y = OH, Cy3, or Cy5) were microinjected in cells and incubated in phenol red-free DMEM containing 2% (v/v) CS in the presence of a 5% CO 2 atmosphere at 37 C for the indicated amounts of time prior to imaging.
Details of microinjection and imaging are provided in the Supplemental Experimental Procedures.
Extract Preparation and In Vitro miRNA Unwinding Assay
Cell extracts were prepared as described (Kwak and Tomari, 2012; Rakotondrafara and Hentze, 2011) , with minor modifications detailed in Supplemental Experimental Procedures. Further details on other methods are provided in the Supplemental Experimental Procedures.
Xenograft Studies
All experimental procedures involving mice were approved by the University Committee on Use and Care of Animals at the University of Michigan and conform to their relevant regulatory standards and are detailed in the Supplemental Experimental Procedures. 
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
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